In a recent study and in line with our finding, CD19+CD25highFoxP3high B regulatory cells were found to be increased in the cerebrospinal fluid of active patients suffering from relapsing-remitting multiple sclerosis (MS) when compared to that of nonclinically active MS. This evidence concerns the gene CD19 and myeloid sarcoma.